Risnia

Basic Risnia information

• INN (international nonproprietary name): Risperidone (also referenced as Risperidonum in Latin).
• Brand names available in the United Kingdom: Risperdal (originator by Janssen‑Cilag) and licensed generic risperidone.
• ATC code: N05AX08.
• Forms and strengths: tablets 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg.
• Oral solution: 1 mg/mL.
• Orally disintegrating tablets (ODT / M‑tab): 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg.
• Manufacturers: Janssen‑Cilag (Johnson & Johnson) as originator, and generics from Teva, Mylan, Sandoz, Sun Pharma, Torrent Pharmaceuticals, Intas and Cadila.
• Registration status in the United Kingdom: Prescription only (Rx).
• OTC / Rx classification: Prescription only (Rx).

Legal status and availability in the UK

In our online pharmacy, Risnia is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

What outcomes can be expected?

Risperidone is commonly prescribed for schizophrenia and acute bipolar mania.

When started and titrated promptly, risperidone produces measurable reductions in positive symptoms such as hallucinations, delusions and agitation.

Common adherence barriers include sedation, weight gain and sexual dysfunction linked to raised prolactin.

Routine monitoring in UK practice includes weight, fasting glucose, lipids, blood pressure and movement disorder checks.

Indications and expanded uses

What is licensed and what is used off‑label?

In the UK, risperidone is licensed for schizophrenia, moderate to severe manic episodes in bipolar disorder, short‑term treatment of persistent aggression in Alzheimer’s dementia, and short‑term treatment of persistent aggression in conduct disorder in children from 5 years and adolescents.

Dementia‑related psychosis is contraindicated due to increased mortality risk and is not an approved indication.

ODT forms may contain aspartame and therefore are important to avoid in patients with phenylketonuria (PKU).

Licensed versus off‑label uses

• Licensed: schizophrenia.
• Licensed: bipolar mania.
• Licensed (short term): persistent aggression in Alzheimer’s dementia or in conduct disorder in children.
• Off‑label (documented multidisciplinary decisions): irritability associated with autism spectrum disorder; Severe agitation in acute settings; adjunctive therapy for treatment‑resistant anxiety or behavioural disturbance where alternatives have failed.

Governance checklist for off‑label use

• Document multidisciplinary rationale and informed consent.
• Agree monitoring frequency up front (metabolic and movement disorder checks).
• Set a planned review date and stop/continuation criteria.
• Record counselling about risks such as prolactin rise and sedation.

Composition and brand landscape

What formulations are available in the UK?

Active ingredient: risperidone (INN).

ATC: N05AX08.

Formulations include tablets (0.25–4 mg), oral solution (1 mg/mL) and orodispersible M‑Tab/ODT (0.5–4 mg).

Originator: Janssen‑Cilag markets Risperdal and Risperdal M‑Tab.

Multiple generics supply tablets and oral solution, including Teva, Mylan, Sandoz and Sun Pharma.

Risnia is an international brand name for risperidone.

Formulation mapping and suppliers

Originator versus generics

• Originator: Risperdal (Janssen‑Cilag).
• Generics: Teva, Mylan, Sandoz, Sun Pharma, Torrent, Intas, Cadila.

Contraindications and special precautions

Who needs extra caution or should avoid risperidone?

Absolute contraindications are known hypersensitivity to risperidone and dementia‑related psychosis in elderly patients.

ODT forms may contain aspartame and are contraindicated in patients with phenylketonuria (PKU).

Caution is advised in cardiovascular disease because of QT prolongation risk.

Use with care in epilepsy, Parkinson’s disease and in patients with diabetes or metabolic syndrome.

Renal and hepatic impairment require lower starting doses and slower titration.

Pregnancy and breastfeeding should prompt a multidisciplinary review, and abrupt withdrawal should be avoided.

Checklist for special precautions

• Confirm absence of PKU before prescribing ODT forms.
• Assess baseline cardiac risk and ECG if indicated.
• Start elderly patients on lower doses (0.25–0.5 mg BID) and titrate slowly.
• Monitor blood glucose and lipids regularly in patients with metabolic risk factors.
• Advise avoiding abrupt discontinuation to reduce relapse risk.

PKU and dementia risk — quick facts

ODT forms may contain aspartame/phenylalanine — contraindicated in phenylketonuria (PKU).

Dementia‑related psychosis is not an approved indication and carries an increased mortality risk.

Dosage guidelines

How is risperidone typically prescribed in NHS practice?

Schizophrenia in adults is typically started at 1 mg twice daily with a common target range of 4–6 mg/day.

Product guidance allows dose increases up to 16 mg/day in divided doses, although most UK practice aims for lower target ranges dependent on response and tolerability.

Bipolar mania is frequently initiated at 2–3 mg once daily and titrated according to response up to 6 mg/day.

Paediatric starts are lower: schizophrenia from around 13 years with initial doses such as 0.5–1 mg/day and cautious titration.

For persistent aggression in conduct disorder, children from 5 years start at 0.25–0.5 mg/day depending on body weight, adjusted individually.

Elderly patients should start at lower doses (0.25–0.5 mg twice daily) and be titrated carefully.

Renal or hepatic impairment warrants lower starting doses and closer monitoring.

Missed dose advice is to take as soon as remembered unless close to the next dose; do not double up.

Dosing table by indication and age

Dose adjustment rules

• Start low and increase slowly in children and the elderly.
• Reduce starting dose in renal or hepatic impairment and monitor clinically.
• If a dose is missed, take as soon as remembered unless it is near the next scheduled dose.
• Avoid abrupt discontinuation; plan a supervised taper when stopping.

Interactions overview

Which medicines and substances affect risperidone?

Risperidone is metabolised primarily by CYP2D6 to 9‑hydroxyrisperidone (paliperidone).

Strong CYP2D6 inhibitors such as fluoxetine and paroxetine can increase risperidone plasma levels and may prompt dose review.

Concurrent use with other QT‑prolonging drugs increases cardiac risk.

Alcohol potentiates sedation and can worsen metabolic adverse effects.

Interaction‑related adverse events are more likely in older patients taking multiple medicines; suspected side effects can be reported via the Yellow Card scheme.

Pharmacist‑led medication reviews are recommended to identify high‑risk concomitant prescriptions.

High‑risk interacting drugs

• CYP2D6 inhibitors: Fluoxetine, Paroxetine.
• Other antipsychotics or antidepressants that prolong QT interval.
• CNS depressants including alcohol and some benzodiazepines.
• Drugs lowering seizure threshold in patients with epilepsy should be used cautiously.

CYP2D6 interaction table

Comparable medicines and prescribing preferences

When might clinicians choose an alternative?

Major comparators in NHS practice include olanzapine, quetiapine, aripiprazole, haloperidol and paliperidone.

Pros of risperidone include established efficacy, multiple formulations and generally lower metabolic risk than olanzapine.

Cons include higher prolactin and EPS risk relative to aripiprazole and notable weight gain compared with some alternatives.

Choice depends on symptom profile, prior response, metabolic history and adherence considerations.

Pros and cons

• Pros: Versatile formulations (tablets, ODT, oral solution, LAI), known efficacy for positive symptoms and mania.
• Cons: Prolactin elevation, EPS risk at higher doses, metabolic side effects that require monitoring.
• Consider LAI for adherence issues and olanzapine for severe insomnia or severe negative symptoms where metabolic status is acceptable.

Decision table for common clinical scenarios

FAQ

Q: Will risperidone make me gain weight?

A: Weight gain is common with risperidone; routine monitoring of weight, fasting glucose and lipids is standard and lifestyle support should be offered.

Q: Can I drink alcohol while taking risperidone?

A: Patients are advised to avoid alcohol because of additive sedation and potential worsening of metabolic effects; discuss occasional use with your prescriber.

Q: Is risperidone available as a long‑acting injection?

A: Yes — Risperdal Consta is a long‑acting injectable that may be used for adherence difficulties; discuss clinic‑based administration with your care team.

Q: What if I miss a dose?

A: Take the missed dose as soon as you remember unless it is close to your next scheduled dose; do not double up.

When to contact your GP or NHS 111: contact them if you experience severe drowsiness, new or worsening movement symptoms, signs of infection on antipsychotic therapy, or suicidal thoughts.

Guidelines for proper use

How should pharmacists counsel patients in UK practice?

Confirm the indication and formulation before supply and check for PKU in patients who may receive ODT forms.

Review concomitant medicines for CYP2D6 inhibitors and QT‑prolonging drugs.

Advise patients about possible sedation, sexual side effects and the importance of metabolic monitoring.

Storage guidance: store at 20–25°C and protect from excessive moisture and heat.

Oral solution should be used within three months of opening as per product information and packaging instructions.

Pharmacist counselling checklist

• Confirm formulation, dose and indication before supply.
• Check for PKU when dispensing ODT forms.
• Explain missed‑dose guidance and the need to avoid alcohol.
• Arrange or prompt baseline monitoring (weight, BP, fasting glucose, lipids).
• Encourage registration and use of NHS patient portals for medication records.

Monitoring schedule

Useful patient information sources: NHS and MHRA guidance pages for antipsychotic monitoring and adverse‑event reporting.

Delivery across the United Kingdom